Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tislelizumab + cisplatin + gemcitabine + trilaciclib + Stempeucel
- Development stage
- Unknown
- Lead developer
- BeiGene
- Modality
- Small Molecules, Stem Cell Therapies → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Intraarticular
01
Overview
This entry represents a non-existent therapeutic combination that appears to be a concatenation of two distinct clinical trial regimens: an oncology chemo-immunotherapy protocol and a regenerative medicine product for osteoarthritis. The oncology components include **tislelizumab** (a humanized IgG4 anti-PD-1 monoclonal antibody), **cisplatin** (a platinum-based cytotoxic agent), **gemcitabine** (a nucleoside analog), and **trilaciclib** (a transient CDK4/6 inhibitor used to protect bone marrow from chemotherapy-induced toxicity). The second component, identified via the developer Stempeutics Research, is **Stempeucel**, an allogeneic, culture-expanded, bone marrow-derived mesenchymal stem cell (MSC) therapy. Stempeucel is administered via intraarticular injection to treat Grade 2-3 knee osteoarthritis by leveraging the immunomodulatory and regenerative properties of MSCs. There is no clinical or biological rationale for combining these five agents into a single treatment for osteoarthritis.
- Brand names
- CoselaStempeucel
- Other names
- tislelizumab + cisplatin + gemcitabine + trilaciclib-Stempeutics Research Pvt Ltd-osteoarthritis of the knee
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)RNR (Ribonucleotide reductase)CDK6 (Cyclin-dependent kinase 6)CDK4 (Cyclin-dependent kinase 4)DNA
Beyond the preview
Go deeper on tislelizumab + cisplatin + gemcitabine + trilaciclib + Stempeucel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tislelizumab + cisplatin + gemcitabine + trilaciclib + Stempeucel.